April 15 (Reuters) - Regeneron Pharmaceuticals ( REGN )

said on Monday the U.S. Justice Department's complaint against

the company misreporting the average sales price for its macular

degeneration drug Eylea is "meritless" and it plans to defend

this case in court.

The Justice Department last week had accused Regeneron of

manipulating Medicare's drug-pricing process by inflating the

average sales price for its Eylea drug.